Brief: Liminal BioSciences Provides Update On Its Lead Drug Candidate Fezagepras

Liminal BioSciences

14/03/2022 12:10

March 14 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * LIMINAL BIOSCIENCES PROVIDES UPDATE ON ITS LEAD DRUG
CANDIDATE
FEZAGEPRAS
    * LIMINAL BIOSCIENCES INC - PLANNED PHASE 1A SINGLE
ASCENDING DOSE
("SAD") TRIAL, COMMENCING IN Q2 2022
    * LIMINAL BIOSCIENCES INC - ANALYSIS OF PK DATA FROM PHASE 1
MULTI-ASCENDING DOSE ("MAD") CLINICAL TRIAL COMPLETED
    * LIMINAL BIOSCIENCES INC - EXPECT TO HAVE DATA FROM PHASE
1A SAD
TRIAL IN Q3 OF 2022

Source text for Eikon:  ID:nCNWVPJKHa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))